Delayed Urticaria- Angioedema After mRNA Vaccine in an Adolescent Patient: Case Report

IF 0.3 Q4 ALLERGY

Astim Allerji Immunoloji Pub Date : 2023-04-07 DOI:10.21911/aai.057AsthmaAllergyImmunol2022

O. Ozdemir, Ummugulsum Dikici, Olena Erkun

{"title":"Delayed Urticaria- Angioedema After mRNA Vaccine in an Adolescent Patient: Case Report","authors":"O. Ozdemir, Ummugulsum Dikici, Olena Erkun","doi":"10.21911/aai.057AsthmaAllergyImmunol2022","DOIUrl":null,"url":null,"abstract":"Messenger RNA (mRNA) vaccines have long been suggested as encouraging candidates for widespread vaccination since they are manufactured rapidly and induce both humoral and cellular immune system components against pathogens. Available data on the efficacy and safety of these vaccines are relatively limited and the spectrum of skin reactions is still unclear. We would like to contribute to the literature by presenting a rare case with cutaneous reactions and discussing the skin complications of these kinds of vaccines. Our patient was a 17-year-old healthy female patient who applied to the pediatric emergency department with urticarial plaques that started from the legs and spread to the trunk nearly 80 hours after the second dose of the BioNTech-Pfizer COVID-19 vaccine was applied. The patient, whose skin lesions recurred more severely within 24 hours at home, and who noticed mild swelling in the fingers of the right hand and on the lip, was brought to the emergency service for the second time. Patients and physicians should be aware of the risk of delayed adverse skin reactions as well as the development of immediate hypersensitivity reactions such as urticaria and angioedema after administration of an mRNA COVID-19 vaccine.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Astim Allerji Immunoloji","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21911/aai.057AsthmaAllergyImmunol2022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Messenger RNA (mRNA) vaccines have long been suggested as encouraging candidates for widespread vaccination since they are manufactured rapidly and induce both humoral and cellular immune system components against pathogens. Available data on the efficacy and safety of these vaccines are relatively limited and the spectrum of skin reactions is still unclear. We would like to contribute to the literature by presenting a rare case with cutaneous reactions and discussing the skin complications of these kinds of vaccines. Our patient was a 17-year-old healthy female patient who applied to the pediatric emergency department with urticarial plaques that started from the legs and spread to the trunk nearly 80 hours after the second dose of the BioNTech-Pfizer COVID-19 vaccine was applied. The patient, whose skin lesions recurred more severely within 24 hours at home, and who noticed mild swelling in the fingers of the right hand and on the lip, was brought to the emergency service for the second time. Patients and physicians should be aware of the risk of delayed adverse skin reactions as well as the development of immediate hypersensitivity reactions such as urticaria and angioedema after administration of an mRNA COVID-19 vaccine.

查看原文本刊更多论文

一例青少年患者接种信使核糖核酸疫苗后出现迟发性荨麻疹-血管水肿的病例报告

信使RNA (mRNA)疫苗长期以来一直被认为是令人鼓舞的广泛接种候选疫苗，因为它们生产迅速，并诱导体液和细胞免疫系统成分对抗病原体。关于这些疫苗的有效性和安全性的现有数据相对有限，皮肤反应的范围仍然不清楚。我们希望通过提出一个罕见的皮肤反应病例，并讨论这类疫苗的皮肤并发症，以促进文献。我们的患者是一名17岁的健康女性患者，在bionech - pfizer第二次接种COVID-19疫苗近80小时后，因荨麻疹斑块从腿部开始扩散到躯干而申请儿科急诊科。患者在家中24小时内皮肤病变复发更严重，并注意到右手手指和嘴唇轻度肿胀，第二次被送到急诊室。患者和医生应意识到注射mRNA COVID-19疫苗后出现延迟性皮肤不良反应的风险，以及出现荨麻疹和血管性水肿等即时超敏反应的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Astim Allerji Immunoloji ALLERGY-

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： Asthma Allergy Immunology has been published three times a year in April, August and December as the official and periodical journal of the Turkish National Society of Allergy and Clinical Immunology since 2003. All articles published in the journal have been available online since 2003. A peer reviewed system is used in evaluation of the manuscripts submitted to Asthma Allergy Immunology. The official language of the journal is English. The aim of the journal is to present advances in the field of allergic diseases and clinical immunology to the readers. In accordance with this goal, manuscripts in the format of original research, review, case report, articles about clinical and practical applications and editorials, short report and letters to the editor about allergic diseases and clinical immunology are published in the journal. The target reader population of the Asthma Allergy Immunology includes specialists and residents of allergy and clinical immunology, pulmonology, internal medicine, pediatrics, dermatology and otolaryngology as well as physicians working in other fields of medicine interested in allergy and immunological diseases.